Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PLRZBullishCorporate Developmentsnews

Medium materiality5/10

Polyrizon gains BRANY IRB approval to initiate NASARIX nasal allergy trial

Jun 29, 2026, 8:50 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

IRB approval reduces clinical development risk and clears path toward site activation; historically, micro-cap biotech trials progressing milestones can trigger upside, though ultimate payoff requires later-stage data and regulatory approvals.

AI summary

What happened, with direct paths to the underlying reporting

Polyrizon Ltd. announced BRANY IRB central approval to begin its first human trial of NASARIX, a nasal spray designed to block airborne allergens. The study, titled NASARIX Allergy Blocker vs saline in seasonal allergic rhinitis, requires site-specific approvals after core IRB clearance, with the master file valid through June 17, 2027. Progress could bolster sentiment around Polyrizon's C&C hydrogel platform.

Polyrizon gains BRANY IRB approval to begin NASARIX trial.
Study compares NASARIX to saline in seasonal allergic rhinitis.
IRB approval valid through June 17, 2027; site approvals pending.
Polyrizon describes NASARIX as a hydrogel nasal barrier.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.